Description:
Semaglutide is the newest GLP-1R agonist and was approved by the FDA as a once-weekly injection for the
treatmentof T2DM in late 2017. The peptide is chemically similar to liraglutide, with the inclusion of two structural
modifications(Lau, Bloch, et al., 2015). The first is the replacement of Gly with the non-proteinogenic amino acid
2-aminoisobutyricacid (Aib) at position 2. The second is the attachment of octadecanoic diacid to the side chain of
Lys-26 through a short polyethylene glycol (PEG) spacer and a γ-glutamic acid linker. The amino acid substitution
renders the peptide more resistant to DPP-4 compared to liraglutide, and the presence of the 18-carbon fatty acid
moiety results in a high binding affinity for serum albumin, which translates to a half-life of approximately 7 days in
humans.
Function&Application:
1.Weight loss
2.Anti-diabetes
3.Alzheimer's disease
Complaint
